Trial Profile
A Phase 2, Open-Label, Single Center, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF-Rho in Patients With Chronic Neutropenia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegfilgrastim ANF (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Prolong Pharmaceuticals
- 04 Mar 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Sep 2015 New trial record